Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
We recently compiled a list of the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2024. In this article, we are going to ...
This study presents important findings on cold tolerance shared between hibernating and non-hibernating mammals, identifying a key molecule, GPX4, through multi-species genome-wide CRISPR screens. The ...
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...
“This enables the model to predict how small DNA changes affect an organism’s fitness, generate realistic genome-length ...
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of ...
Dr. Shyam Sundar Nandi from the National Institute of Virology has created a rapid mpox testing kit that delivers results in ...
The Thanksgiving pull has arrived, and produce markets have more than a few things to be grateful for, says ProduceIQ.
Healthcare Asia on MSN14h
Global regenerative medicine market to grow by $70.11b by 2028It is driven by developments in personalised medicine, gene therapy, and CRISPR technology. The global regenerative medicine ...
Biohacking is not now limited to tech-savvy rebels, it is an experiment on human evolution itself. Whether we are ready to face the music or not, biohacking is already at our doorstep. While ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback